CLYM

$15.98+$1.25 (+8.49%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$826.5M

57M shares

52-week range

$1.54 – $16.21

98% from low

Sector

PHARMACEUTICAL PREPARATIONS

Exchange

NASDAQ

Change+$10.88

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$0	—	$-0.87	$-1.17–$-0.70	—	10
2027	$750000	—	$-1.03	$-1.35–$-0.80	—	10
2028	$937500	+25.0%	$-1.43	$-3.05–$-0.92	—	11
2029	$4M	+352.8%	$-1.86	$-1.86–$-1.86	—	4

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 4 of the last 7 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-06	$-0.21	$-0.18	+14.0%
2026-05-07	$-0.26	$-0.20	+23.1%
2026-03-05	$-0.20	$-0.26	-30.0%
2025-11-06	$-0.16	$-0.19	-18.8%
2025-08-12	$-0.19	$-0.13	+31.6%
2025-05-14	$-0.15	$-0.31	-106.7%
2025-03-25	$-0.15	$-0.13	+13.3%

DCF fair valuemodel estimate

Intrinsic value

$0.49

Price

$15.98

Implied downside

-97%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
CLYMClimb Bio, Inc.	$15.96	+8.33%	$914M	—
ABOSAcumen Pharmaceuticals, Inc.	$2.54	-0.59%	$183M	—
ACTUActuate Therapeutics Inc	$0.97	-0.78%	$23M	—
AGENAgenus Inc.	$7.24	+3.41%	$301M	—
ANIXAnixa Biosciences, Inc.	$3.17	-0.94%

Climb Bio, Inc. Common Stock

Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.

www.climbbio.com

Employees: 29
IPO / List date: Aug 10, 2021
HQ: WELLESLEY HILLS, MA

Held by traders on TradeandTell

No one on the platform currently holds CLYM.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	217,300	$1.5M

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded CLYM yet.

$CLYM chatter on StockTwits

peter schaedel@shadeBullish7m
$CLYM good news is coming
View on StockTwits ↗
Cache Money@Cache_Money40m
$CLYM 👀
View on StockTwits ↗
StockConsultant.com@StockConsultant2d
$CLYM Climb Bio stock, watch for a top of range breakout at https://www.stockconsultant.com/?CLYM Breakout trade WATCH for possible breakout above 14.55 Target: 17.44, 21.3% Stop: 13.52 Loss: 5.9% P/L ratio: 3.6 : 1 - Excellent BULLISH [Positioning] Intermediate trend possibly bullish, Mild uptrend. [Timing] Strong bullish 3 day candlestick pattern with Mild 3 day accumulation. [Timing] breakout watch above 14.55, no resistance in area just above. BEARISH [Positioning] Short term typical rally, rally may start to slow. [Positioning] at resistance
View on StockTwits ↗
j@Jusprag244d
$CLYM Going to run up a bit over the next month or so.
View on StockTwits ↗
Cache Money@Cache_MoneyAug 3
$CLYM It’s weird that out of the large pharma companies only Amgen has a non-CAR-T CD19 depleter. If and only if Climb’s phase 2 data looks good this is actually an asset a larger company might want. Not only for the B cell-driven diseases but also for combo treatment for conditions that are more of a mix of B and T cells (e.g. most of the major autoimmune disorders).
View on StockTwits ↗
Cache Money@Cache_MoneyAug 3
$CLYM Was doing a deep dive tonight into the role of plasma cells and alpha v beta 6 autoantibodies in UC and started looking at which companies could offer CD19 B cell depletion in a safer and cheaper format than a CAR-T. While Climb Bio isn’t testing their CD19 monoclonal for UC they do have very exciting phase 2 readouts coming up in Q4 of this year for three other autoimmune conditions, including pMN, ITP and SLE. It’s behind in SLE (but administered subq while Uplizna has to be given IV) but a leader for the other two, and all three indications are thought to be mainly driven by B cells. Taking a position here.
View on StockTwits ↗
H Green@DOLEMITEMFUHEARDHERJul 15
$CLYM stop selling
View on StockTwits ↗
Dan@DanzzzzzzzzJul 6
$BMEA simple... $TNGX ... $1.1 in may 2025. Now around 32. $$EDSA ... 0.73 a few months ago. Rallied up to $20 a couple mobths ago. A few good ones too: $CLYM $RNAC $TECX
View on StockTwits ↗
Capt. kubota@kubota2323Jul 6
$CLYM
View on StockTwits ↗
Quantumup@QuantumupJun 24
H.C. Wainwright on $CLYM (Buy; $20): Budoprutug clinical data in idiopathic thrombocytopenic purpura underscores therapeutic potential. $NVS $SNY AMGN UCBJY TAK H.C. Wainwright added—Climb Bio recently reported initial data from the ongoing Phase 1b portion of its Phase 1b/2a study evaluating budoprutug, an anti-CD19 monoclonal antibody, in adults with primary immune thrombocytopenia (ITP) demonstrating an encouraging safety and tolerability profile, robust B-cell depletion, and meaningful platelet responses in heavily pretreated patients. The initial data were presented at the European Hematology Association (EHA) Congress 2026, which was held on June 11-14, 2026, in Stockholm, Sweden. Results to date support continued clinical evaluation of budoprutug in ITP; we reiterate our Buy rating and 12-month price target of $20.
View on StockTwits ↗
StockConsultant.com@StockConsultantJun 23
$CLYM Climb Bio stock, nice trend, watch for a top of range breakout at https://stockconsultant.com/?CLYM Breakout trade WATCH for possible breakout above 12.56 Target: 15.16, 24.4% Stop: 11.12 Loss: 8.7% P/L ratio: 2.8 : 1 - Good BULLISH [Timing] Strong bullish 3 day candlestick pattern with Strong 3 day accumulation. [Timing] Strong bullish 1 day moneyflow [Timing] breakout watch above 12.56, no resistance in area just above. BEARISH [Positioning] 1 Day Price change strong up, may pause [Positioning] Intermediate trend possibly bearish, Uptrend turned sideways, may continue or pullback. [Positioning] at resistance
View on StockTwits ↗
jorge .miguel@focafoca99Jun 12
$CLYM structured an Open Market Sale Agreement with Jefferies to sell up to $100 million of common stock, and also terminated its prior
View on StockTwits ↗
Quantumup@QuantumupJun 11
BTIG⬆️ $CLYM's PT to $20 (was $19),⬆️budoprutug in ITP to 65% while reiterating at Buy $SNY NVS $AMGN VERA VRTX NVS TVTX OTSKY Here's what BTIG said in its note: https://x.com/Quantumup1/status/2065120495209484563?s=20
View on StockTwits ↗
Open Outcrier@OpenOutcrierJun 11
$CLYM (+6.0% pre) Climb Bio reports initial phase 1b data for budoprutug in blood disorder https://ooc.bz/l/104829
View on StockTwits ↗
jorge .miguel@focafoca99Jun 11
$CLYM outlined early Phase 1b/2a data showing budoprutug boosted platelet counts and achieved >90% B‑cell depletion in ITP patients.
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.